You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PLOS this week: mitochondrial mutation linked to tubulointerstitial kidney disease, asthma protection variant, and more.
The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.
The company plans to use the funds to build up a Dublin-based genomic research and development program based on the model of Iceland's Decode Genetics.
The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.
A study in NEJM found that rare, loss-of-function mutations in the asialoglycoprotein receptor gene coincide with lower non-HDL levels and decreased coronary artery disease risk.
DeCode Genetics' Kari Stefansson and his colleagues uncovered a dozen genetic variants that influence blood lipids, and explored links to coronary artery disease.
Amgen has posted three of its failed efforts to confirm findings from high-profile journal articles online to encourage others to do likewise.
The tests analyze tumor samples for mutations oncogenes including KRAS and NRAS in order to help guide treatment decisions for patients with metastatic colorectal cancer.
DeCode's Kari Stefansson and his colleagues report that creativity and conditions like schizophrenia and bipolar disorder share a genetic source.
Drug companies are rushing toward genomic databases to inform their searches for new drugs, Reuters reports.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.